Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced results from a study co-sponsored by InMed and the University of British Columbia. Notably, this study is the first ever to report hydrogel-mediated cannabinoid nanoparticle delivery to the eye resulting in enhanced drug uptake via the cornea and lens. “Importantly, this study offers further validation of InMed’s capabilities in moving the science of cannabinoid pharmaceuticals forward,” Eric A. Adams, president and CEO of InMed, stated in the news release. “Results like this, combined with our expanding patent portfolio and list of publications, on-going R&D, and renowned scientific team and collaborators demonstrates our depth of know-how and supports our trajectory to becoming an industry leader.” Per this morning’s update, the study also validated InMed’s capacity to conduct a wide spectrum of drug development activities, including biosynthesis of a cannabinoid using a novel E. coli-based system, packaging of the cannabinoid as a nanoparticle, formulation of a cannabinoid drug candidate into a novel, tissue specific delivery vehicle and confirmation of drug delivery and diffusion into a target tissue.
To view the full press release, visit http://nnw.fm/2EIBu
About InMed
InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.
More from NetworkNewsBreaks
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
